Application of multi-target peptide in preparation of analgesic drug
Patent Information
- Application Number
- CN202410917728.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
[0004]本发明的目的是为了解决现有技术中缺乏镇痛效果显著且副作用小的缓解慢性疼痛的药物
[0037] (1) Compared with solid-phase synthesis one by one, the liquid-phase fragment synthesis method of the compounds disclosed in the present invention has fewer by-products (defective peptides) during the preparation process and reduces the difficulty and cost of purification.
Smart Images

Figure CN118878633A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to application of a multi-target peptide in the preparation of analgesic drugs. Background Art
[0002] Chronic pain is a common and intractable disease with a complex pathogenesis. It not only affects the normal function of the body, but also induces various complications / comorbidities (such as mood disorders and sleep disorders), impairs people's quality of life, and causes huge socioeconomic losses. At present, there is a serious shortage of analgesics suitable for patients with chronic pain in clinical practice, the treatment effect is poor, and the adverse reactions of the drugs are large. For example, opioids, which are the first-line drugs in clinical practice, usually cause adverse reactions such as analgesic tolerance, addiction, physical dependence, respiratory depression, calmness and nausea, which reduce the patient's medication experience and have a negative impact on the patient's life, thus greatly limiting their application in the treatment of chronic pain.
[0003] In recent years, the opioid crisis caused by the abuse of opioid analgesics has become a public health issue that cannot be ignored. Therefore, there is an urgent need for drugs that can relieve chronic pain with significant analgesic effects and few side effects. Summary of the invention
[0004] The purpose of the present invention is to solve the problem that the prior art lacks a drug for relieving chronic pain with significant analgesic effect and few side effects.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] A polypeptide, the molecular weight of the polypeptide is 1582.78 g / mol, and the amino acid sequence of the polypeptide is
[0007] Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH.
[0008] Preferably, the chemical structural formula of the polypeptide is as follows:
[0009]
[0010] Preferably, the preparation method of the polypeptide is as follows:
[0011] S1: The following peptide fragments were synthesized by liquid phase method:
[0012] First peptide fragment: Boc-Dmt-N-Me-d-Ala-Trp-Phe-OH
[0013] Second peptide fragment: H-Ile-Ser-Tyr-Gly-Gly-OH
[0014] The third peptide fragment: H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH
[0015] S2: condensing the above polypeptide fragments in a liquid phase system;
[0016] S3: removing the ester protecting group on the carboxyl group of the side chain of the aspartic acid residue, the Fmoc-group in the lysine side chain, the Boc-group on the amino group of the N-terminal isoleucine, and the Boc-group at the N-terminus to obtain a crude peptide;
[0017] S4: Crude peptide purification.
[0018] A polypeptide according to claim 3, characterized in that: in S2, in the liquid phase system, the first peptide fragment and the second peptide fragment are preferentially condensed, and then condensed with the third peptide fragment.
[0019] Preferably, the first fragment synthesis step is as follows:
[0020] Synthesis of Boc-Dmt-N-Me-d-Ala-OH′
[0021] Synthesis of H-Trp-Phe-OH′
[0022] Synthesis of Boc-Dmt-N-Me-d-Ala-Trp-Phe-OH.
[0023] Preferably, the second peptide fragment synthesis step is as follows:
[0024] Synthesis of Boc-Ile-Ser-OH;
[0025] Synthesis of Boc-Tyr-Gly-OH;
[0026] Synthesis of H-Tyr-Gly-Gly-OH;
[0027] Synthesis of Boc-Ile-Ser-Tyr-Gly-Gly-OH;
[0028] Synthesis of H-Ile-Ser-Tyr-Gly-Gly-OH.
[0029] Preferably, the third peptide fragment synthesis step is as follows:
[0030] Synthesis of Boc-Ala-Asp(OMe)-OH;
[0031] Synthesis of H-Tyr-Lys(Fmoc)-OH;
[0032] Synthesis of H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH.
[0033] Preferably, the specific steps of purifying the crude peptide in S4 are as follows: by reverse high performance liquid chromatography (HPLC) C 18 The column was prepared, the mobile phase was acetonitrile (containing 0.1% trifluoroacetic acid) and deionized water (containing 0.1% trifluoroacetic acid), the main peak sample was collected after separation, and the pure peptide white solid powder was obtained after freeze-drying.
[0034] The present application also provides an application of a polypeptide in the preparation of an analgesic drug for the treatment of chronic pain, wherein the polypeptide is the polypeptide described above.
[0035] Preferably, the therapeutic targets of the polypeptide are Mu-opioid receptor (μOR) and programmed cell death receptor (PD-1).
[0036] Compared with the prior art, this application has the following beneficial effects:
[0037] (1) Compared with solid-phase synthesis one by one, the liquid-phase fragment synthesis method of the compound disclosed in the present invention has fewer by-products (defective peptides) during the preparation process, reducing the difficulty and cost of purification.
[0038] (2) The polypeptide disclosed in the present invention can activate μOR and PD-1 receptor simultaneously. Compared with traditional opioid drugs, it can effectively avoid the risk of over-activation of opioid receptors and inducing adverse reactions;
[0039] (3) Compared with the traditional opioid analgesic drug morphine, the compounds disclosed in the present invention have a highly effective and long-lasting analgesic effect on chronic neuropathic pain;
[0040] (4) Compared with the traditional opioid drug morphine, the compounds disclosed in the present application have significantly reduced side effects, higher safety, and potential clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 This is an ESI-MS spectrum of the polypeptide WK-11 in one embodiment of the present invention;
[0042] Figure 2 This is a graph showing an analgesic effect of the polypeptide WK-11 in an embodiment of the present invention on pathological neuralgia induced by chronic compression injury of the sciatic nerve;
[0043] Figure 3 This is a comparison chart of the analgesic effects of morphine and peptide WK-11 in CCI mice after oral administration for 7 consecutive days. DETAILED DESCRIPTION
[0044] The following are the abbreviations and structural comparisons of the compounds involved in this application:
[0045]
[0046]
[0047] The present invention is further described in detail below in conjunction with specific embodiments.
[0048] The present application provides a polypeptide (WK-11), which can activate opioid receptors and PD-1 receptors at the same time. The molecular weight of the polypeptide is 1582.78 g / mol, and the amino acid sequence and chemical structure are as follows:
[0049] Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH
[0050]
[0051] The present application also provides a method for preparing the above polypeptide, the preparation method comprising the following steps:
[0052] S1: The following peptide fragments were synthesized by liquid phase method:
[0053] First peptide fragment: Boc-Dmt-N-Me-d-Ala-Trp-Phe-OH
[0054] Second peptide fragment: H-Ile-Ser-Tyr-Gly-Gly-OH
[0055] The third peptide fragment: H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH
[0056] S2: condensing the above polypeptide fragments in a liquid phase system;
[0057] In the liquid phase system, the first peptide fragment is preferentially condensed with the second peptide fragment, and then condensed with the third peptide fragment;
[0058] S3: removing the ester protecting group on the carboxyl group of the side chain of the aspartic acid residue, the Fmoc-group in the lysine side chain, the Boc-group on the amino group of the N-terminal isoleucine, and the Boc-group at the N-terminus to obtain a crude peptide;
[0059] S4: Crude peptide purification:
[0060] Specifically, in one embodiment, the crude peptide is purified by a reverse phase high performance liquid chromatography column (RP-HPLC preparative column) to obtain the target peptide.
[0061] The present application also provides the above polypeptide for use in the preparation of analgesic drugs for treating chronic pain. In one embodiment, the drug is a drug for relieving neuropathic pain.
[0062] In one embodiment, the therapeutic targets of the polypeptide are Mu-opioid receptor (μOR) and programmed cell death receptor (PD-1).
[0063] In one embodiment, the drug can be applied to various currently known administration methods, such as intrathecal administration, subcutaneous administration, tail vein administration, oral administration, etc.
[0064] The above contents are described below in combination with specific embodiments and related verification experiments:
[0065] Example 1: Synthesis of polypeptide:
[0066] 1. Synthesis of the first peptide fragment
[0067] 1.1. Synthesis of Boc-Dmt-N-Me-d-Ala-OH
[0068] Boc-Dmt-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of HN-Me-d-Ala-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 12 hours. After the reaction, dichloromethane was added to dilute the mixture, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried with anhydrous sodium sulfate, and distilled under reduced pressure to obtain an oily product Boc-Dmt-N-Me-d-Ala-OH with a yield of 97%.
[0069] 1.2. Synthesis of H-Trp-Phe-OH
[0070] Boc-Trp-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Phe-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried with anhydrous sodium sulfate, and distilled under reduced pressure to obtain an oily product Boc-Trp-Phe-OH with a yield of 99%.
[0071] Boc-Trp-Phe-OH (1 mol) was dissolved in a mixed solution of dichloromethane / trifluoroacetic acid (v:v=1:1), and the reaction was carried out at room temperature for 1 hour. After the reaction was completed, the oily product H-Trp-Phe-OH.TFA was obtained by distillation under reduced pressure with a yield of 99%. The oily product H-Trp-Phe-OH.TFA was dissolved in a saturated sodium bicarbonate solution to obtain a saturated sodium bicarbonate solution of H-Trp-Phe-OH.
[0072] 1.3 Synthesis of Boc-Dmt-N-Me-d-Ala-Trp-Phe-OH
[0073] Boc-Dmt-N-Me-d-Ala-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Trp-Phe-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 24 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried over anhydrous sodium sulfate, and distilled under reduced pressure to obtain a white solid product Boc-Dmt-N-Me-d-Ala-Trp-Phe-OH with a yield of 93%.
[0074] 2. Synthesis of the second peptide fragment H-Ile-Ser-Tyr-Gly-Gly-OH
[0075] 2.1 Synthesis of Boc-Ile-Ser-OH
[0076] Boc-Ile-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Ser-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried with anhydrous sodium sulfate, and distilled under reduced pressure to obtain an oily product Boc-Ile-Ser-OH with a yield of 98%.
[0077] 2.2 Synthesis of Boc-Tyr-Gly-OH
[0078] Boc-Tyr-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Gly-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried with anhydrous sodium sulfate, and distilled under reduced pressure to obtain an oily product Boc-Tyr-Gly-OH with a yield of 95%.
[0079] 2.3 Synthesis of H-Tyr-Gly-Gly-OH
[0080] Boc-Tyr-Gly-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Gly-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried with anhydrous sodium sulfate, and distilled under reduced pressure to obtain a white solid product Boc-Tyr-Gly-Gly-OH with a yield of 96%.
[0081] Boc-Tyr-Gly-Gly-OH (1 mol) was dissolved in a mixed solution of dichloromethane / trifluoroacetic acid (v:v=1:1), and the reaction was carried out at room temperature for 1 hour. After the reaction, it was distilled under reduced pressure to obtain an oily product H-Tyr-Gly-Gly-OH.TFA with a yield of 99%. It was dissolved in a saturated sodium bicarbonate solution to obtain a saturated sodium bicarbonate solution of H-Tyr-Gly-Gly-OH.
[0082] 2.4 Synthesis of Boc-Ile-Ser-Tyr-Gly-Gly-OH
[0083] Boc-Ile-Ser-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Tyr-Gly-Gly-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 24 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried with anhydrous sodium sulfate, and distilled under reduced pressure to obtain a white solid product Boc--Ile-Ser-Tyr-Gly-Gly-OH with a yield of 90%.
[0084] 2.5. Synthesis of H-Ile-Ser-Tyr-Gly-Gly-OH
[0085] Boc-Ile-Ser-Tyr-Gly-Gly-OH (1 mol) was dissolved in a mixed solution of dichloromethane / trifluoroacetic acid (v:v=1:1), and the reaction was carried out at room temperature for 1 hour. After the reaction, the oily product H-Ile-Ser-Tyr-Gly-Gly-OH.TFA was obtained by vacuum distillation with a yield of 98%. The oily product H-Ile-Ser-Tyr-Gly-Gly-OH.TFA was dissolved in a saturated sodium bicarbonate solution to obtain a saturated sodium bicarbonate solution of H-Ile-Ser-Tyr-Gly-Gly-OH.
[0086] 3. Synthesis of the third peptide fragment H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH
[0087] 3.1. Boc-Ala-Asp(OMe)-OH
[0088] Boc-Ala-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Asp(OMe)-OH (1.2 mol) was added, and the reaction was carried out at room temperature for 12 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times and saturated sodium chloride once, dried with anhydrous sodium sulfate, and distilled under reduced pressure to obtain an oily liquid product Boc-Ala-Asp(OMe)-OH with a yield of 93%.
[0089] 3.2 Synthesis of H-Tyr-Lys(Fmoc)-OH
[0090] Boc-Tyr-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Lys(Fmoc)-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried with anhydrous sodium sulfate, and distilled under reduced pressure to obtain a white solid product Boc-Tyr-Lys(Fmoc)-OH with a yield of 96%.
[0091] Boc-Tyr-Lys(Fmoc)-OH (1 mol) was dissolved in a mixed solution of dichloromethane / trifluoroacetic acid (v:v=1:1), and the reaction was carried out at room temperature for 1 hour. After the reaction was completed, the oily product H-Tyr-Lys(Fmoc)-OH.TFA was obtained by distillation under reduced pressure with a yield of 98%. The oily product H-Tyr-Lys(Fmoc)-OH.TFA was dissolved in a saturated sodium bicarbonate solution.
[0092] 3.3. H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH
[0093] Boc-Ala-Asp(OMe)-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Tyr-Lys(Fmoc)-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 24 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried over anhydrous sodium sulfate, and distilled under reduced pressure to obtain a white solid product Boc-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH with a yield of 92%.
[0094] Boc-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH (1 mol) was dissolved in a mixed solution of dichloromethane / trifluoroacetic acid (v:v=1:1), and the reaction was carried out at room temperature for 1 hour. After the reaction was completed, the oily product H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH.TFA was obtained with a yield of 98%. The oily product H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH.TFA was obtained, and the oily product H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH.TFA was obtained. The oily product H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH.TFA was obtained by dissolving the oily product in a saturated sodium bicarbonate solution to obtain a saturated sodium bicarbonate solution of H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH.
[0095] 4. Synthesis of Boc-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-OH
[0096] Boc-Dmt-N-Me-d-Ala-Trp-Phe-OH (1 mol) was dissolved in dichloromethane, and N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, a saturated sodium bicarbonate solution of H-Ile-Ser-Tyr-Gly-Gly-OH (1.2 mol) was added, and the mixture was reacted at room temperature for 24 hours. After the reaction was completed, dichloromethane was added for dilution, and the mixture was washed with 5% sodium citrate 3 times, saturated sodium chloride once, dried over anhydrous sodium sulfate, and distilled under reduced pressure to obtain a white solid product Boc-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-OH; the yield was 86%.
[0097] 5. Synthesis of H-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH
[0098] 5.1. Synthesis of Boc-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH
[0099] Boc-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-OH (1 mol) was dissolved in dichloromethane. N,N-diisopropylethylamine (3 mol), 1-hydroxybenzotriazole (1.5 mol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5 mol) were added under stirring at 0°C. After reacting for 10 minutes, H-Ala-Asp(OMe)-Tyr-Lys(Fm oc)-OH (1.2 mol) saturated sodium bicarbonate solution, react at room temperature for 48 hours. After the reaction, dichloromethane was added to dilute, washed with 5% sodium citrate 3 times, washed with saturated sodium chloride once, dried over anhydrous sodium sulfate, and distilled under reduced pressure to obtain a white solid product Boc-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH with a yield of 80%.
[0100] Boc-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH (1 mol) was dissolved in tetrahydrofuran, and a 2.5 N aqueous solution of NaOH was added. The mixture was reacted at room temperature for 12 hours. After the reaction was completed, the mixture was distilled under reduced pressure. The pH of the aqueous phase was adjusted under stirring at 0°C until a large amount of white solid precipitated. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and distilled under reduced pressure to obtain a white solid.
[0101] Boc-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH, 95% yield.
[0102] 5.2. Synthesis of H-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH:
[0103] Boc-Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH was dissolved in a mixed solution of dichloromethane / trifluoroacetic acid (1:1), reacted at 0°C with stirring for 1 hour, and evaporated under reduced pressure to obtain H-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH.TFA.
[0104] 6. Purification of target peptide
[0105] Reverse phase high performance liquid chromatography (HPLC) 18 The column was prepared, and the mobile phase was acetonitrile (containing 0.1% trifluoroacetic acid) and deionized water (containing 0.1% trifluoroacetic acid). After separation, the main peak sample was collected and freeze-dried to obtain a pure peptide white solid powder. The crude peptide loading amount was 100 mg. After purification and freeze-drying, 51 mg of the target peptide WK-11 with a purity of 98% was obtained, and the pure peptide yield was 51%. Mass spectrometry identification was as follows Figure 1 shown.
[0106] Example 2: Surface plasmon resonance (SPR) assay to evaluate the binding ability of peptides to opioid receptors and PD-1
[0107] In this experiment, human recombinant proteins (OPRM1 / OPRD1 / OPRK1 / PD-1) were loaded onto CM5 chips using aminocarboxyl coupling reagents, and the binding constants between peptides and proteins were analyzed using the biacore x100 system.
[0108] The experimental results of SPR showed that the KD of peptide WK-11 and human OPRM1 recombinant protein was 24.6±0.1μM, the KD of peptide WK-11 and human OPRD1 recombinant protein was 33.2±1.2mM, the KD of peptide WK-11 and OPRK1 was 56.1±3.8mM, and the KD of peptide WK-11 and human PD-1 protein was 45±2.5μM. The results of the binding experiment confirmed that peptide WK-11 had good binding ability with both Mu-opioid receptor and PD-1.
[0109] Example 3: Experiment on chronic neuralgia caused by sciatic nerve compression injury
[0110] Chronic compression injury (CCI) of the sciatic nerve was established by making three ligatures with surgical sutures 5 mm proximal to the trifurcated branch of the sciatic nerve. After 14 days of modeling, the changes in the mechanical pain threshold of mice before and after drug administration were evaluated by a single injection and repeated oral administration for seven days.
[0111] The experimental results are as follows Figure 2 As shown. By oral administration, at a dose of 1 mg / kg, the target peptide can significantly improve the mechanical pain sensitivity of CCI-mice and can last for 5 hours. Compared with the traditional opioid drug morphine, the analgesic dose required is less and the duration of the drug effect is longer. In addition, after knocking out the OPRM1 gene or the Pdcd1 gene, the analgesic effect of the peptide WK-11 was completely reversed. The results of the in vivo experiment were consistent with the results of the SPR experiment, indicating that the peptide WK-11 mainly produces analgesic effects by acting on PD-1 and Mu-opioid receptors at the same time.
[0112] In summary, the polypeptide WK-11 provided by the present invention can simultaneously activate Mu-opioid and PD-1 receptors, and in the mouse chronic neuropathic pain model, it shows an analgesic effect that is better than morphine, with fewer side effects, and has good clinical application prospects in the preparation of analgesic drugs.
Claims
1. A polypeptide, characterized in that: The molecular weight of the polypeptide is 1582.78 g / mol, and the amino acid sequence of the polypeptide is Dmt-N-Me-d-Ala-Trp-Phe-Ile-Ser-Tyr-Gly-Gly-Ala-Asp-Tyr-Lys-OH.
2. A polypeptide according to claim 1, characterized in that: The chemical structural formula of the polypeptide is as follows:
3. A polypeptide according to claim 1, characterized in that: The preparation method of the polypeptide is as follows: S1: The following peptide fragments were synthesized by liquid phase method: First peptide fragment: Boc-Dmt-N-Me-d-Ala-Trp-Phe-OH Second peptide fragment: H-Ile-Ser-Tyr-Gly-Gly-OH The third peptide fragment: H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH S2: condensing the above polypeptide fragments in a liquid phase system; S3: removing the ester protecting group on the carboxyl group of the side chain of the aspartic acid residue, the Fmoc-group in the lysine side chain, the Boc-group on the amino group of the N-terminal isoleucine, and the Boc-group at the N-terminus to obtain a crude peptide; S4: Crude peptide purification.
4. A polypeptide according to claim 3, characterized in that: In the S2, in the liquid phase system, the first peptide fragment is preferentially condensed with the second peptide fragment, and then condensed with the third peptide fragment.
5. A polypeptide according to claim 3, characterized in that: The first fragment synthesis step is as follows: Synthesis of Boc-Dmt-N-Me-d-Ala-OH; Synthesis of H-Trp-Phe-OH; Synthesis of Boc-Dmt-N-Me-d-Ala-Trp-Phe-OH.
6. A polypeptide according to claim 3, characterized in that: The synthesis steps of the second peptide fragment are as follows: Synthesis of Boc-Ile-Ser-OH; Synthesis of Boc-Tyr-Gly-OH; Synthesis of H-Tyr-Gly-Gly-OH; Synthesis of Boc-Ile-Ser-Tyr-Gly-Gly-OH; Synthesis of H-Ile-Ser-Tyr-Gly-Gly-OH.
7. A polypeptide according to claim 3, characterized in that: The synthesis steps of the third peptide fragment are as follows: Synthesis of Boc-Ala-Asp(OMe)-OH; Synthesis of H-Tyr-Lys(Fmoc)-OH; Synthesis of H-Ala-Asp(OMe)-Tyr-Lys(Fmoc)-OH.
8. A polypeptide according to claim 3, characterized in that: The specific steps of crude peptide purification in S4 are as follows: by reverse high performance liquid chromatography (HPLC) C 18 The column was prepared, the mobile phase was acetonitrile (containing 0.1% trifluoroacetic acid) and deionized water (containing 0.1% trifluoroacetic acid), the main peak sample was collected after separation, and the pure peptide white solid powder was obtained after freeze-drying.
9. Use of a polypeptide in the preparation of an analgesic drug for the treatment of chronic pain, characterized in that: The polypeptide is the polypeptide according to any one of claims 1 to 8.
10. The use according to claim 9, characterized in that: The therapeutic targets of the polypeptide are Mu-opioid receptor (μOR) and programmed cell death receptor (PD-1).
